Importer of Controlled Substances Application: PerkinElmer, Inc., 10475-10476 [2020-03620]

Download as PDF 10475 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Drug code Controlled substance Pentobarbital ............................................................................................................................................................................ Secobarbital ............................................................................................................................................................................. Glutethimide ............................................................................................................................................................................. Nabilone ................................................................................................................................................................................... 1-Phenylcyclohexylamine ........................................................................................................................................................ Phencyclidine ........................................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................................. Phenylacetone ......................................................................................................................................................................... 1-Piperidinocyclohexanecarbonitrile ........................................................................................................................................ Alphaprodine ............................................................................................................................................................................ Anileridine ................................................................................................................................................................................ Cocaine .................................................................................................................................................................................... Codeine ................................................................................................................................................................................... Etorphine HCl .......................................................................................................................................................................... Dihydrocodeine ........................................................................................................................................................................ Oxycodone ............................................................................................................................................................................... Hydromorphone ....................................................................................................................................................................... Diphenoxylate .......................................................................................................................................................................... Ecgonine .................................................................................................................................................................................. Ethylmorphine .......................................................................................................................................................................... Hydrocodone ........................................................................................................................................................................... Levomethorphan ...................................................................................................................................................................... Levorphanol ............................................................................................................................................................................. Isomethadone .......................................................................................................................................................................... Meperidine ............................................................................................................................................................................... Meperidine intermediate-A ...................................................................................................................................................... Meperidine intermediate-B ...................................................................................................................................................... Meperidine intermediate-C ...................................................................................................................................................... Metazocine .............................................................................................................................................................................. Methadone ............................................................................................................................................................................... Methadone intermediate .......................................................................................................................................................... Metopon ................................................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) ...................................................................................................................... Morphine .................................................................................................................................................................................. Oripavine ................................................................................................................................................................................. Thebaine .................................................................................................................................................................................. Dihydroetorphine ..................................................................................................................................................................... Levo-alphacetylmethadol ......................................................................................................................................................... Oxymorphone .......................................................................................................................................................................... Noroxymorphone ..................................................................................................................................................................... Phenazocine ............................................................................................................................................................................ Thiafentanil .............................................................................................................................................................................. Piminodine ............................................................................................................................................................................... Racemethorphan ..................................................................................................................................................................... Racemorphan .......................................................................................................................................................................... Alfentanil .................................................................................................................................................................................. Remifentanil ............................................................................................................................................................................. Sufentanil ................................................................................................................................................................................. Carfentanil ............................................................................................................................................................................... Tapentadol ............................................................................................................................................................................... Bezitramide .............................................................................................................................................................................. Fentanyl ................................................................................................................................................................................... Moramide-intermediate ............................................................................................................................................................ The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers. lotter on DSKBCFDHB2PROD with NOTICES Dated: February 3, 2020. William T. McDermott, Assistant Administrator. DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–589] [FR Doc. 2020–03612 Filed 2–21–20; 8:45 am] ACTION: Notice of application. BILLING CODE 4410–09–P Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on DATES: VerDate Sep<11>2014 18:30 Feb 21, 2020 Jkt 250001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II or before March 25, 2020. Such persons may also file a written request for a hearing on the application on or before March 25, 2020. Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug ADDRESSES: Importer of Controlled Substances Application: PerkinElmer, Inc. 2270 2315 2550 7379 7460 7471 8333 8501 8603 9010 9020 9041 9050 9059 9120 9143 9150 9170 9180 9190 9193 9210 9220 9226 9230 9232 9233 9234 9240 9250 9254 9260 9273 9300 9330 9333 9334 9648 9652 9668 9715 9729 9730 9732 9733 9737 9739 9740 9743 9780 9800 9801 9802 Schedule E:\FR\FM\24FEN1.SGM 24FEN1 10476 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on January 13, 2020, PerkinElmer, Inc., 120 E Dedham Street, Boston, Massachusetts 02118–2852 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance Drug code Lysergic acid diethylamide .............................................................................................................................................. Thebaine .......................................................................................................................................................................... The company plans to import the listed controlled substances in bulk for manufacturing wherein the controlled substances will be labeled with a radioactive tracer compound and sold for research purposes to its customers. Thebaine (9333) will be used to manufacture the derivative Diprenorphine. Dated: January 31, 2020. William T. McDermott, Assistant Administrator. [FR Doc. 2020–03620 Filed 2–21–20; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB Number 1190–0008] Agency Information Collection Activities, Proposed eCollection eComments Requested Extension Without Change, of a Previously Approved Collection; Federal Coordination and Compliance Section (FCS); FCS Complaint and Consent Form Civil Rights Division, Department of Justice. ACTION: 30-Day notice. AGENCY: The Department of Justice (DOJ), Civil Rights Division, Federal Coordination and Compliance Section, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: The Department of Justice encourages public comment and will accept input until March 25, 2020. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Christine Stoneman, Acting Chief, Federal Coordination and Compliance Section, 950 Pennsylvania Avenue NW– lotter on DSKBCFDHB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:30 Feb 21, 2020 Jkt 250001 4CON, Washington, DC 20002 (phone: 202–307–2222). SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Extension of a currently approved collection. 2. The Title of the Form/Collection: Complaint and Consent Form. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form number is 1190–0008. The applicable component within the Department of Justice is the Federal Coordination and Compliance Section, in the Civil Rights Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: General public. Information is used to find jurisdiction to investigate the alleged discrimination, to seek whether a referral to another agency is necessary and to provide information needed to PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 7315 9333 Schedule I II initiate investigation of the complaint. Respondents are individuals. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 4000 respondents will complete each form within approximately 30 minutes. 6. An estimate of the total public burden (in hours) associated with the collection: There are an estimated 2000 total annual burden hours associated with this collection. If additional information is required contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, Room 3E.405A, Washington, DC 20530. Dated: February 18, 2020. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2020–03544 Filed 2–21–20; 8:45 am] BILLING CODE 4410–13–P DEPARTMENT OF JUSTICE [OMB Number 1122–0034] Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Currently Approved Collection Office on Violence Against Women, Department of Justice. ACTION: 60-Day notice. AGENCY: The Department of Justice, Office on Violence Against Women (OVW) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until April 24, 2020. FOR FURTHER INFORMATION CONTACT: Written comments and/or suggestion regarding the items contained in this notice, especially the estimated public SUMMARY: E:\FR\FM\24FEN1.SGM 24FEN1

Agencies

[Federal Register Volume 85, Number 36 (Monday, February 24, 2020)]
[Notices]
[Pages 10475-10476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03620]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-589]


Importer of Controlled Substances Application: PerkinElmer, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before March 25, 2020. Such 
persons may also file a written request for a hearing on the 
application on or before March 25, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug

[[Page 10476]]

Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette 
Drive, Springfield, Virginia 22152; and (2) Drug Enforcement 
Administration, Attn: DEA Federal Register Representative/DPW, 8701 
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on January 13, 2020, PerkinElmer, Inc., 120 E Dedham 
Street, Boston, Massachusetts 02118-2852 applied to be registered as an 
importer of the following basic classes of controlled substances:

------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide.........            7315  I
Thebaine...........................            9333  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances in 
bulk for manufacturing wherein the controlled substances will be 
labeled with a radioactive tracer compound and sold for research 
purposes to its customers. Thebaine (9333) will be used to manufacture 
the derivative Diprenorphine.

    Dated: January 31, 2020.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-03620 Filed 2-21-20; 8:45 am]
BILLING CODE 4410-09-P